Attovia Therapeutics/$ATTO
1D1W1MYTD1Y5YMAX
Capital at risk
About Attovia Therapeutics
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
- Ticker
- $ATTO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 44
- Headquarters
- San Carlos, United States
- Website
- www.attovia.com
ATTO Metrics
BasicAdvanced
$1B
-
-$17.01
-
-
Price and volume
Market cap
$1B
52-week high
$28.00
52-week low
$16.15
Average daily volume
286K
Financial strength
Current ratio
9.386
Quick ratio
9.198
Long term debt to equity
0.02
Total debt to equity
0.038
Profitability
EBITDA (TTM)
-75.251
Gross margin (TTM)
-3,469.94%
Net profit margin (TTM)
-3,910.00%
Operating margin (TTM)
-4,232.94%
Revenue per employee (TTM)
$40,000
Management effectiveness
Valuation
Price to revenue (TTM)
50.697
Price to book
-0.69
Price to tangible book (TTM)
-0.69
Price to free cash flow (TTM)
-1.338
Free cash flow yield (TTM)
-74.76%
Free cash flow per share (TTM)
-16.552
Growth
What the Analysts think about ATTO
Analyst ratings (Buy, Hold, Sell) for Attovia Therapeutics stock.
Analyst projections of the future price of Attovia Therapeutics stock.
Bulls say / Bears say
Attovia’s IPO filing reveals backing by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio—each holding at least 5%—and names Morgan Stanley, Leerink Partners, Citigroup, and RBC Capital Markets as lead underwriters, underscoring strong institutional confidence (Reuters translation via Boursorama)
In its upsized offering, Attovia priced 17 million shares at $17 apiece to raise $289 million at a targeted $731.5 million valuation, reflecting robust investor demand for biotechnology listings (Reuters)
Attovia closed its IPO on August 6, 2026 with the underwriters’ full exercise of their 30‐day overallotment, increasing total shares to 19.55 million and gross proceeds to approximately $332.4 million, bolstering its cash runway for clinical development (Attovia IR)
As a clinical‐stage biotech with no approved drugs or product revenue, Attovia’s prospectus cautions that it may encounter unforeseen R&D challenges and delays common to early‐stage companies, highlighting the binary risk of its pipeline failing to deliver viable therapies (SEC Prospectus)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
ATTO Financial Performance
Revenues and expenses
ATTO Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.